Regulatory Roundup: EMA Issues Concept Paper for Public Consultation on Development of Toxicological Guidance for use in Risk Identification - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: EMA Issues Concept Paper for Public Consultation on Development of Toxicological Guidance for use in Risk Identification

ePT--the Electronic Newsletter of Pharmaceutical Technology

EMA’s Committee for Medicinal Products for Human Use has issued a concept paper for public consultation on the development of toxicological guidance for use in risk identification in the manufacture of different medicinal products in shared facilities. The paper is based on the current “lack of clarity in the existing GMP guide with respect to when a medicinal product should be manufactured in dedicated facilities.” The paper includes a proposal to revise certain sections of the GMP guide (3.6, 5.18, and 5.19), including the incorporation of quality risk management principles as described in the ICH Q9 guideline. The consultation period will close in January 2012 and a revised draft is expected in May 2012. Following that, a draft and final guidance will be issued by the first half of 2013, with a 6-month implementation deadline for industry.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here